

CPTC-TRAF3-2 (CAB080283)

Uniprot ID: Q13114

Protein name: TRAF3_HUMAN

Full name: TNF receptor-associated factor 3

Function: Cytoplasmic E3 ubiquitin ligase that regulates various signaling pathways, such as the NF-kappa-B, mitogen-activated protein kinase (MAPK) and interferon regulatory factor (IRF) pathways, and thus controls a lot of biological processes in both immune and non-immune cell types (PubMed:33148796, PubMed:33608556). In TLR and RLR signaling pathways, acts as an E3 ubiquitin ligase promoting the synthesis of 'Lys-63'-linked polyubiquitin chains on several substrates such as ASC that lead to the activation of the type I interferon response or the inflammasome (PubMed:25847972, PubMed:27980081). Following the activation of certain TLRs such as TLR4, acts as a negative NF-kappa-B regulator, possibly to avoid unregulated inflammatory response, and its degradation via 'Lys-48'-linked polyubiquitination is required for MAPK activation and production of inflammatory cytokines. Alternatively, when TLR4 orchestrates bacterial expulsion, TRAF3 undergoes 'Lys-33'-linked polyubiquitination and subsequently binds to RALGDS, mobilizing the exocyst complex to rapidly expel intracellular bacteria back for clearance (PubMed:27438768). Acts also as a constitutive negative regulator of the alternative NF-kappa-B pathway, which controls B-cell survival and lymphoid organ development. Required for normal antibody isotype switching from IgM to IgG. Plays a role T-cell dependent immune responses. Down-regulates proteolytic processing of NFKB2, and thereby inhibits non-canonical activation of NF-kappa-B. Promotes ubiquitination and proteasomal degradation of MAP3K14.

Subcellular location:

Cytoplasm (*experimental evidence*)

Endosome (*by similarity*)


Mitochondrion (*experimental evidence*)

NOTE: Undergoes endocytosis together with TLR4 upon LPS signaling (By similarity). Co-localized to mitochondria with TRIM35 (PubMed:32562145).

Protein existence: Experimental evidence at protein level


Comment:

Immunohistochemistry




IHC protocol:	HIER pH6, Dilution 1:300
IHC test staining:	Negative in all tissues.
Literature conformance:	Not consistent with gene/protein characterization data
Literature significance:	
RNA similarity:	Very low consistency between antibody staining and RNA expression data
RNA tissue specificity:	Low tissue specificity
RNA tissue distribution:	Detected in all
IHC Sibling similarity:	Other antibody shows dissimilar IHC staining pattern
IHC fail comment:	ANTIBODY FAILED: Not consistent with RNA

Immunofluorescence



IF Overlay:	antibody (green), anti-tubulin (red) and DAPI (blue)
IF main location:	
IF additional location:	
IF approved for publication on HPA:	No
IF in THP-1:	Negative
IF in U-2 OS:	Negative

Western blot



WB Size markers (kDa):	250, 130, 100, 70, 55, 35, 25, 15, 10
WB Lanes:	Marker (1), RT4 (2), U-251 MG (3), Plasma (4), Liver (5), Tonsil (6)
WB Target weight (kDa):	10, 34, 55, 62, 62, 64, 64
WB Validation:	Uncertain (No bands detected.)